A closer look at Parkinson’s brains finds tau where standard tests saw little

By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Jul 29 2026

By examining six brain regions at single-molecule resolution, researchers identified a layer of tau pathology that conventional tissue staining could not fully capture.

Study: Nanoscopic tau aggregates in Parkinson’s disease. Image Credit: peterschreiber.media / Shutterstock

In a recent study published online as an 'article in press' in the journal npj Parkinson's Disease, researchers used single-molecule pull-down (SiMPull) assays and super-resolution microscopy to map nanoscopic distributions of protein aggregates in post-mortem human brain tissue.

The study specifically analyzed six distinct brain regions using tissue from 29 post-mortem donors, although sample availability varied by region, and identified a distinct population of high-intensity, nanoscopic phosphorylated tau (pTau) aggregates in the putamen of Parkinson's disease (PD) cases. The putamen is a region where standard immunohistochemistry showed negligible tau staining in this cohort.

The study further revealed that these nanoscopic tau aggregates ranged in length from 30 to 800 nanometers, while pTau intensity was inversely correlated with alpha-synuclein (αSyn) immunohistochemical coverage in the amygdala. Furthermore, tau aggregate burden was highest on average among the five PD cases with recorded dementia, whereas single-molecule assays did not identify a PD-specific population of nanoscopic αSyn species.

Background

Classical neuropathological evaluation of Parkinson's disease (PD) typically focuses on alpha-synuclein aggregation into insoluble Lewy bodies and dopaminergic cell loss in the midbrain substantia nigra. Emerging biophysical research, however, suggests that these large inclusion bodies may represent later-stage sequestration products rather than the primary toxic species.

These studies indicate the presence of smaller, highly soluble intermediate species, termed nanoscopic aggregates. A growing body of experimental evidence suggests that these nanoscopic aggregates may be more toxic than mature fibrils, although their effects in the human brain remain uncertain.

Unfortunately, while post-mortem tau pathology is documented in up to 50% of PD dementia cases, conventional immunohistochemistry (IHC) cannot reliably resolve or characterize the smallest sub-diffraction aggregates. As a result, whether nanoscopic tau accumulation is a specific feature of PD or reflects coincident age-related tauopathy remained unclear.

About the study

The present study aimed to resolve these pathological dynamics by systematically profiling soluble nanoscopic aggregates and insoluble inclusions across six key brain regions: the hippocampus, amygdala, substantia nigra, putamen, frontal cortex, and occipital cortex.

The study’s primary sample cohort comprised 29 post-mortem cases, or donated brains, which the authors categorized into three distinct study groups: 1. Individuals with idiopathic PD (n = 14; five with recorded dementia), 2. Non-PD control cases with age-related tau pathology (AR-tau; n = 7, predominantly Braak stage III), and 3. Controls with minimal neuropathology (Braak stage 0-II; n = 8). Additionally, 9 Alzheimer's disease (AD) putamen samples (Braak stages III-VI) were evaluated to enable cross-disease benchmarking.

To differentiate aggregate populations, the researchers combined DAB immunohistochemistry on formalin-fixed tissue with single-molecule pull-down (SiMPull) assays performed on fresh-frozen soluble tissue fractions.

The study’s quantitative endpoints evaluated aggregate density, estimated detection-antibody binding per aggregate as an intensity-based measure of aggregate size, multi-color fluorophore colocalization (HT7 for total tau, AT8 and pT181 for pTau, Syn211 for αSyn), and DNA-PAINT super-resolution length measurements. The presence of putaminal pTau aggregates was additionally examined in situ in three PD and three control samples using stimulated emission depletion (STED) microscopy.

SiMPull workflow and output for characterising protein aggregates. (a) Post-mortem brain tissue cohort overview. The SN was highlighted due to the reduced sample size for frozen tissue. (b) IHC was used to study large, insoluble inclusion bodies. (c) Schematic representation of SiMPull used to detect nanoscopic aggregates. SiMPull excludes monomers from detection by using identical capture and detection antibodies. (d) Examples of diffraction-limited imaging using tau SiNaP aggregate standards. Aggregate density was significantly correlated with tau SiNaP concentration (Pearson correlation). Each point represents the mean of 12 FOVs and three well replicates, error bars represent mean ± standard deviation. (e) “Auto” contrast-adjusted example images of HT7 dipeptide, tau SiNaPs, and corresponding aggregate intensity distributions. (f) Example images of HT7 imaged in Channel (Ch) 1, AT8 imaged in Ch2. The white arrow indicates the same object in each channel and the merged image that was colocalised. (g) Example DNA-PAINT images from one PD human brain sample. Insets (i) and (ii) feature close-ups of super-resolved pTau aggregates. HIP = Hippocampus; AMYG = Amygdala; PUT = Putamen; SN = Substantia nigra; FC = Frontal cortex; OC = Occipital cortex. SiNaP = silica nanoparticle; FOV = Field of view; pTau = phosphorylated tau.

Study findings

The study’s SiMPull analysis revealed that total tau intensity was bimodal. The low-intensity population peak (1-10 antibodies/aggregate) was interpreted as corresponding to physiological multimers. The high-intensity population (10-1,000 antibodies/aggregate) instead marked disease-associated species.

Notably, while standard IHC showed negligible tau staining in the putamen, SiMPull identified a previously undetected, PD-associated increase in high-intensity pTau aggregates in the putamen (p = 0.007 vs. controls; p = 0.030 vs. AR-tau).

DNA-PAINT super-resolution imaging confirmed that these putaminal pTau aggregates formed fibrillar structures ranging between 30 and 800 nm in length. In cross-disease comparisons with AD putamen tissue, mid-Braak-stage AD (III-IV) showed predominantly low-intensity total-tau aggregates, while advanced AD (V-VI) showed higher pTau aggregate intensity than PD (p = 0.003) and mid-stage AD (p = 0.015).

These findings support the possibility that nanoscopic tau accumulation may precede visible inclusion formation. In the amygdala of PD cases, pTau SiMPull intensity was inversely correlated with αSyn IHC coverage (ρ = -0.61, p = 0.04), suggesting a complex relationship between Lewy body pathology and nanoscopic tau accumulation, although the mechanism and direction of this relationship remain uncertain.

Descriptive subgroup comparisons further showed that PD cases with dementia had the highest average nanoscopic pTau aggregate burden in both the medial temporal lobe and the putamen. Conversely, αSyn SiMPull did not identify a distinct nanoscopic aggregate population in PD brains. Importantly, 87.8% of αSyn signals in PD bound fewer than five detection antibodies and were interpreted as low-order physiological multimers, consistent with dimers and tetramers detected using native PAGE.

Conclusions

This study provides evidence that the burden of tau pathology in Parkinson's disease may have been underestimated by conventional immunohistochemical methods. Its findings revealed that soluble, nanoscopic pTau aggregates were detected in the putamen despite negligible visible tau inclusions, suggesting that these species may precede inclusion formation.

The authors emphasize that, while these findings suggest nanoscopic tau may contribute to nigrostriatal neurodegeneration and cognitive decline in some people with advanced PD, the study is limited by its cross-sectional post-mortem design, modest sample sizes within regional subgroups, such as the substantia nigra, and insufficient clinical data to examine relationships with motor impairment.

Beyond these caveats, however, the identification of sub-diffraction pTau species highlights nanoscopic tau as a potential target for future disease-modifying research, although replication and mechanistic evidence are needed before its therapeutic relevance can be established.